AU2002224838B9 - Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases - Google Patents
Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases Download PDFInfo
- Publication number
- AU2002224838B9 AU2002224838B9 AU2002224838A AU2002224838A AU2002224838B9 AU 2002224838 B9 AU2002224838 B9 AU 2002224838B9 AU 2002224838 A AU2002224838 A AU 2002224838A AU 2002224838 A AU2002224838 A AU 2002224838A AU 2002224838 B9 AU2002224838 B9 AU 2002224838B9
- Authority
- AU
- Australia
- Prior art keywords
- seq
- acid sequences
- nucleic acid
- polypeptide
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000032823 cell division Effects 0.000 title claims abstract description 68
- 201000010099 disease Diseases 0.000 title claims abstract description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 38
- 238000003745 diagnosis Methods 0.000 title claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 title abstract description 118
- 230000002062 proliferating effect Effects 0.000 title abstract description 10
- 210000003527 eukaryotic cell Anatomy 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 51
- 230000004663 cell proliferation Effects 0.000 claims abstract description 36
- 238000007423 screening assay Methods 0.000 claims abstract description 20
- 238000002955 isolation Methods 0.000 claims abstract description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 120
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 102
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 102
- 229920001184 polypeptide Polymers 0.000 claims description 101
- 239000012634 fragment Substances 0.000 claims description 60
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 49
- 102000039446 nucleic acids Human genes 0.000 claims description 46
- 108020004707 nucleic acids Proteins 0.000 claims description 46
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 44
- 239000003814 drug Substances 0.000 claims description 38
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 34
- 238000012300 Sequence Analysis Methods 0.000 claims description 27
- 229940079593 drug Drugs 0.000 claims description 27
- 230000002547 anomalous effect Effects 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 18
- 230000002163 immunogen Effects 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 230000002068 genetic effect Effects 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 11
- 230000003993 interaction Effects 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 10
- 230000027455 binding Effects 0.000 claims description 9
- 230000000295 complement effect Effects 0.000 claims description 9
- 206010025323 Lymphomas Diseases 0.000 claims description 8
- 230000001613 neoplastic effect Effects 0.000 claims description 8
- 239000007790 solid phase Substances 0.000 claims description 7
- 201000000054 Coronary Restenosis Diseases 0.000 claims description 6
- 206010056489 Coronary artery restenosis Diseases 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- 238000002372 labelling Methods 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 239000000032 diagnostic agent Substances 0.000 claims description 4
- 229940039227 diagnostic agent Drugs 0.000 claims description 4
- 108020001507 fusion proteins Proteins 0.000 claims description 4
- 102000037865 fusion proteins Human genes 0.000 claims description 4
- 238000011002 quantification Methods 0.000 claims description 4
- 238000003259 recombinant expression Methods 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- 230000002452 interceptive effect Effects 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 19
- 238000011161 development Methods 0.000 abstract description 11
- 230000001028 anti-proliverative effect Effects 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 description 57
- 230000006870 function Effects 0.000 description 29
- 241001465754 Metazoa Species 0.000 description 25
- 230000014509 gene expression Effects 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 25
- 241000282414 Homo sapiens Species 0.000 description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 description 21
- 230000009368 gene silencing by RNA Effects 0.000 description 20
- 239000000523 sample Substances 0.000 description 18
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 17
- 210000001161 mammalian embryo Anatomy 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 239000013598 vector Substances 0.000 description 16
- 210000001109 blastomere Anatomy 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 239000013615 primer Substances 0.000 description 14
- 241000894007 species Species 0.000 description 14
- 210000003793 centrosome Anatomy 0.000 description 13
- 238000001152 differential interference contrast microscopy Methods 0.000 description 13
- 210000002308 embryonic cell Anatomy 0.000 description 13
- 238000003752 polymerase chain reaction Methods 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 230000007547 defect Effects 0.000 description 12
- 210000002257 embryonic structure Anatomy 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 102000029749 Microtubule Human genes 0.000 description 9
- 108091022875 Microtubule Proteins 0.000 description 9
- 210000004688 microtubule Anatomy 0.000 description 9
- 230000010076 replication Effects 0.000 description 9
- 210000004940 nucleus Anatomy 0.000 description 8
- 101000911746 Homo sapiens DCN1-like protein 1 Proteins 0.000 description 7
- 101001008857 Homo sapiens Kelch-like protein 7 Proteins 0.000 description 7
- 229930012538 Paclitaxel Natural products 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 210000002969 egg yolk Anatomy 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 210000004408 hybridoma Anatomy 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 229960001592 paclitaxel Drugs 0.000 description 7
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 7
- 102000001708 Protein Isoforms Human genes 0.000 description 6
- 108010029485 Protein Isoforms Proteins 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
- 102000004243 Tubulin Human genes 0.000 description 6
- 108090000704 Tubulin Proteins 0.000 description 6
- 230000033077 cellular process Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000000394 mitotic effect Effects 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 241000244203 Caenorhabditis elegans Species 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 5
- 102100026982 DCN1-like protein 1 Human genes 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000010196 hermaphroditism Effects 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000031016 anaphase Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 210000004718 centriole Anatomy 0.000 description 4
- 230000010129 centrosome duplication Effects 0.000 description 4
- 230000021953 cytokinesis Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 230000011278 mitosis Effects 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000016853 telophase Effects 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- 102000036364 Cullin Ring E3 Ligases Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000206602 Eukaryota Species 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000244206 Nematoda Species 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000001594 aberrant effect Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000003149 assay kit Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000006369 cell cycle progression Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000001054 cortical effect Effects 0.000 description 3
- 230000002548 cytokinetic effect Effects 0.000 description 3
- 238000002224 dissection Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002887 multiple sequence alignment Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000000869 mutational effect Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000012203 pronuclear migration Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000020347 spindle assembly Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 239000012539 chromatography resin Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000005094 computer simulation Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 230000007457 establishment of nucleus localization Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000034839 mitotic sister chromatid segregation Effects 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 230000023999 pseudocleavage Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000007046 spindle assembly involved in mitosis Effects 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 108010029675 Bacillus licheniformis alpha-amylase Proteins 0.000 description 1
- 108091005658 Basic proteases Proteins 0.000 description 1
- 241000537222 Betabaculovirus Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000193764 Brevibacillus brevis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091060290 Chromatid Proteins 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 208000001951 Fetal Death Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 229940121849 Mitotic inhibitor Drugs 0.000 description 1
- 210000004460 N cell Anatomy 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 241000187398 Streptomyces lividans Species 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000005911 anti-cytotoxic effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000023359 cell cycle switching, meiotic to mitotic cell cycle Effects 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 210000004756 chromatid Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000024321 chromosome segregation Effects 0.000 description 1
- 230000031188 cleavage furrow formation Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000007878 drug screening assay Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 231100001129 embryonic lethality Toxicity 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 231100000479 fetal death Toxicity 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 238000002761 liquid phase assay Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000007814 microscopic assay Methods 0.000 description 1
- 230000008880 microtubule cytoskeleton organization Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 230000001423 neocortical effect Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000003757 neuroblast Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 230000017111 nuclear migration Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000012247 phenotypical assay Methods 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 210000004508 polar body Anatomy 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000002407 reforming Methods 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002764 solid phase assay Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 229940072040 tricaine Drugs 0.000 description 1
- FQZJYWMRQDKBQN-UHFFFAOYSA-N tricaine methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=CC([NH3+])=C1 FQZJYWMRQDKBQN-UHFFFAOYSA-N 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000010865 video microscopy Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
- C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
- C07K14/43545—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24675000P | 2000-11-09 | 2000-11-09 | |
| US60/246,750 | 2000-11-09 | ||
| PCT/EP2001/013034 WO2002038805A2 (en) | 2000-11-09 | 2001-11-09 | Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2002224838A1 AU2002224838A1 (en) | 2002-07-25 |
| AU2002224838B2 AU2002224838B2 (en) | 2006-07-27 |
| AU2002224838B9 true AU2002224838B9 (en) | 2007-02-08 |
Family
ID=22932039
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002224838A Ceased AU2002224838B9 (en) | 2000-11-09 | 2001-11-09 | Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases |
| AU2483802A Pending AU2483802A (en) | 2000-11-09 | 2001-11-09 | Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2483802A Pending AU2483802A (en) | 2000-11-09 | 2001-11-09 | Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7368248B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1334123B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2004526421A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE405585T1 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2002224838B9 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2428438C (cg-RX-API-DMAC7.html) |
| DE (1) | DE60135482D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1334123T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002038805A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003070918A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
| US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
| US20050148530A1 (en) | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US7517864B2 (en) | 2001-05-18 | 2009-04-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| EP1432724A4 (en) | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | INTERFERENCE MEDIATION INHIBITION OF GENE RNA FROM MAP KINASE |
| US20070003520A1 (en) * | 2003-11-17 | 2007-01-04 | Brown Susanne M | Mutant viruses |
| EP1713915B1 (en) | 2004-02-10 | 2009-12-16 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING MULTIFUNCTIONAL SHORT INTERFERING NUCLEIC ACID (MULTIFUNCTIONAL siNA) |
| EP1747022A4 (en) | 2004-04-23 | 2010-03-31 | Univ Columbia | INHIBITION OF HAIRLESS PROTEIN MRNA |
| US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
| EP1931789B1 (en) | 2005-09-20 | 2016-05-04 | BASF Plant Science GmbH | Methods for controlling gene expression using ta-siran |
| AU2008228814B2 (en) | 2007-03-21 | 2014-03-06 | Brookhaven Science Associates, Llc | Combined hairpin-antisense compositions and methods for modulating expression |
| MX339050B (es) | 2009-12-18 | 2016-05-09 | Novartis Ag | Composiciones organicas para tratar las enfermedades relacionadas con hsf1. |
| IN2012DN06588A (cg-RX-API-DMAC7.html) | 2010-02-10 | 2015-10-23 | Novartis Ag | |
| US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8910962D0 (en) | 1989-05-12 | 1989-06-28 | Natural Environment Res | Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells |
| US5162222A (en) | 1989-07-07 | 1992-11-10 | Guarino Linda A | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses |
| US5155037A (en) | 1989-08-04 | 1992-10-13 | The Texas A&M University System | Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems |
| CA2311201A1 (en) * | 1999-08-05 | 2001-02-05 | Genset S.A. | Ests and encoded human proteins |
-
2001
- 2001-11-09 DK DK01993708T patent/DK1334123T3/da active
- 2001-11-09 CA CA2428438A patent/CA2428438C/en not_active Expired - Fee Related
- 2001-11-09 EP EP01993708A patent/EP1334123B1/en not_active Expired - Lifetime
- 2001-11-09 DE DE60135482T patent/DE60135482D1/de not_active Expired - Lifetime
- 2001-11-09 JP JP2002542118A patent/JP2004526421A/ja active Pending
- 2001-11-09 AT AT01993708T patent/ATE405585T1/de not_active IP Right Cessation
- 2001-11-09 WO PCT/EP2001/013034 patent/WO2002038805A2/en not_active Ceased
- 2001-11-09 AU AU2002224838A patent/AU2002224838B9/en not_active Ceased
- 2001-11-09 US US10/415,657 patent/US7368248B2/en not_active Expired - Fee Related
- 2001-11-09 AU AU2483802A patent/AU2483802A/xx active Pending
Non-Patent Citations (6)
| Title |
|---|
| D1, EMBL Accession no AL024499 * |
| D2, EMBL Accession no L14745 * |
| D3, EMBL Accession no L10986 * |
| D4, EMBL Accession no C64048 * |
| D5 EMBL Accession no M79698 * |
| D6, EMBL Accession no AF292100 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004526421A (ja) | 2004-09-02 |
| ATE405585T1 (de) | 2008-09-15 |
| WO2002038805A3 (en) | 2003-02-13 |
| AU2483802A (en) | 2002-05-21 |
| EP1334123A2 (en) | 2003-08-13 |
| AU2002224838B2 (en) | 2006-07-27 |
| US7368248B2 (en) | 2008-05-06 |
| EP1334123B1 (en) | 2008-08-20 |
| WO2002038805A2 (en) | 2002-05-16 |
| US20040048277A1 (en) | 2004-03-11 |
| DK1334123T3 (da) | 2009-01-12 |
| CA2428438C (en) | 2012-09-25 |
| WO2002038805A8 (en) | 2007-07-05 |
| DE60135482D1 (de) | 2008-10-02 |
| CA2428438A1 (en) | 2002-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002224838B9 (en) | Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases | |
| AU2002224838A1 (en) | Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases | |
| Fowler et al. | Characterization of hydra type IV collagen: type IV collagen is essential for head regeneration and its expression is up-regulated upon exposure to glucose | |
| JP2003516124A (ja) | 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子 | |
| Ochi et al. | CCDC61/VFL3 is a paralog of SAS6 and promotes ciliary functions | |
| EP1682573B1 (en) | The use of eukaryotic genes affecting cell cycle control or cell cycle progression for diagnosis and treatment of proliferattive diseases | |
| AU2002227917B2 (en) | Genes required for viability and/or reproduction in C. elegans and their use in the development of anti-nematode agents | |
| US7479369B2 (en) | Use of eukaryotic genes affecting spindle formation or microtubule function during cell division for diagnosis and treatment of proliferative diseases | |
| AU2002227917A1 (en) | Genes required for viability and/or reproduction in C. elegans and their use in the development of anti-nematode agents | |
| US20050003363A1 (en) | Method of screening for agents inhibiting chloride intracellular channels | |
| US20070042981A1 (en) | Use of eukaryotic genes affecting chromatin separation for diagnosis and treatment of proliferative diseases | |
| Petzold et al. | Cells determine cell density using a small protein bound to a unique tissue-specific phospholipid | |
| WO2000049048A1 (en) | Ndae1 - a new bicarbonate transporter | |
| Huang | Mutagenesis and functional analysis of dveli, the Drosophila ortholog of C. elegans lin-7 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |